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Cancer-related inflammation is a key component of the tumor microenvironment. A report in this issue of
Cancer Cell now indicates that tumor-associated neutrophils in lung cancer can polarize to either ‘‘N1’’ or
‘‘N2’’ phenotype that inhibits or promotes cancer development, respectively.Inflammatory cells and mediators are
a key component of the tumor microenvi-
ronment (Mantovani et al., 2008) and
cancer-related inflammation has been
proposed to represent the seventh hall-
mark of cancer. Among inflammatory
cells, the ‘‘big eaters,’’ tumor-associated
macrophages (TAMs), have long been
credited to play a key role in tumor pro-
gression (Mantovani et al., 2008; Pollard,
2004). Macrophages can exert dual func-
tions in the context of tumors. M1 macro-
phages activated by interferons and bac-
terial products can elicit tumor- and
tissue-destructive reactions by targeting
cancer cells and the tumor vasculature.
At the other end of the spectrum, in re-
sponse to tumor-derived or lymphocyte-
derived signals (e.g., Hagemann et al.,
2006; DeNardo et al., 2009), TAMs infil-
trate neoplastic tissues and are set in an
M2, alternative activation mode (Manto-
vani et al., 2002). TAMs affect virtually all
aspects of tumor progression, ranging
from cancer cell proliferation and survival,
to angiogenesis, to response to hormones
(Mantovani et al., 2008). A report by Frid-
lender et al. (2009) now highlights that
the ‘‘small eaters’’ (microphages), neutro-
phils, can be no less important in tumor
progression.
Neutrophils are short-lived white blood
cells derived from bone marrow myeloid
precursors. Attention has long been fo-
cused on their short-term antimicrobial
and tissue-damaging function. However,
cytokines, including some involved in
tumor progression such as IL-1, dramati-
cally prolong their survival and reprogram
their function. Moreover, polymorphonu-
clear leukocytes (PMN) are themselves a
conspicuous source of inflammatory cyto-
kines (Cassatella, 2006). Previous studies
have already shown that PMN can pro-
mote cancer in particular by affecting the
angiogenic switch (Pekarek et al., 1995;Nozawa et al., 2006). Fridlender et al.
(2009) now report that in lung cancer
and mesothelioma models, including an
orthotopic primary one, TGF-b blockage
is associated with activation of a CD8+
T cell-dependent effector arm that in-
volves neutrophils as effectors. Under
conditions of TGF-b-mediated immuno-
suppression, CD8+ T cell activation
results in increased recruitment of neutro-
phils, their ‘‘N1’’ polarization, and anti-
tumor activity. Conversely, in the pres-
ence of TGF-b, depletion of ‘‘N2’’
polarized neutrophils results in tumor
growth retardation. Interestingly, prelimi-
nary data suggest that at least part of
the neutrophil-attracting chemokines is
derived from TAMs, suggesting a ‘‘me´-
nage a trois’’ involving T cells, macro-
phages, and PMN. The N1-N2 polariza-
tion of TAN was born out by limited
transcription analysis with similarities to
corresponding macrophage populations,
for instance in terms of arginase levels.
Thus, in models of lung cancer, infiltrating
neutrophils are driven by TGF-b to acquire
a polarized N2 protumor phenotype. After
TGF-b inhibition, a shift to N1 occurs with
acquisition of antitumor activity in vitro
and in vivo.
Interestingly, in a parallel set of studies,
TGF-b was also associated with myelo-
monocytic cell-attracting chemokines
and myeloid cell recruitment. In a mam-
mary carcinoma model, deficiency in the
type II TGF-b receptor was associated
with chemokine-mediated recruitment of
myeloid cells (Yang et al., 2008). These
in turn promoted metastasis via metallo-
proteinase. Thus, TGF-b, a tumor sup-
pressor (but at times a promoter) fre-
quently involved in human tumors and
associated with metastasis, appears to
be generally linked to regulation of che-
mokine production and myelomonocytic
cell recruitment in tumors.Cancer Cell 16,The new findings raise a number of
questions and suggest that the role of
neutrophils in cancer-related inflamma-
tion may need careful reappraisal. The
N1-N2 polarization proposed by Frid-
lender et al. (2009) mirrors the M1-M2
polarization of macrophages. It will be
important to assess whether and to what
extent neutrophil plasticity indeed mirrors
macrophage polarization, by defining for
instance the effect on these cells of inter-
feron-g and IL-4 produced mainly by Th1
and Th2 cells, respectively. Cancer is
associated with the expansion of the my-
eloid compartment and with the appear-
ance of a heterogeneous set of immuno-
suppressive cells operationally defined as
myeloid-derived suppressor cells (MDSC;
Gabrilovich and Nagaraj, 2009). The TAN
characterized in the present study have
clear features of mature neutrophils. Yet,
the general question remains as to the
differentiation in tumor tissues of MDSC
and as to the nature of the ultimate ef-
fectors (neutrophils? macrophages?) of
MDSC-suppressive function. There are
considerable differences between mouse
and human in terms of transcriptional pro-
files associated with macrophage polari-
zation, e.g., arginase expression. There-
fore, the existence and properties of
N1-N2 in humans will have to be carefully
investigated. Finally, the present results
call for a reappraisal of infiltration, polari-
zation, and prognostic significance of
neutrophils in human cancer.
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Very little is known about how acqu
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in chronic myeloid leukemia.
Chronic myeloid leukemia (CML) is a
clonal disease of hematopoietic stem
cells (HSCs) that occurs as a result of a
reciprocal translocation between chro-
mosomes 9 and 22 (Quintas-Cardama
and Cortes, 2009). This rearrangement
gives rise to the Philadelphia (Ph) chromo-
some that, at the molecular level, con-
tains a genomic fusion between the
BCR gene from chromosome 22 and the
ABL1 gene from chromosome 9. ABL1
encodes the Abelson tyrosine kinase,
and its enforced expression from the
BCR-ABL1 gene fusion drives the patho-
genesis of Ph+ leukemias through phos-
phorylation of a wide range of substrates
that regulate cell proliferation, differentia-
tion, migration, survival, and DNA repair.
Clinically, CML follows a triphasic course,
with the majority of patients presenting in
chronic phase characterized by an accu-
mulation of myeloid progenitor cells and
mature granulocytes in the bone marrow
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and peripheral blood. If untreated, the
chronic phase can last several years be-
fore progressing to an accelerated phase
characterized by increasing disease bur-
den and frequently accompanied by the
acquisition of additional genetic defects.
The accelerated phase can last weeks to
months and signals the imminent devel-
opment of blast crisis, the final phase of
CML. Clinically, blast crisis behaves like
acute leukemia and can have an immature
myeloid, pre-B lymphoblastic, or mixed-
lineage phenotype (Garcia-Manero et al.,
2003). The molecular mechanisms in-
volved in the evolution of this complex
disease from chronic phase to blast crisis
remain largely unknown, although it is
clear that genetic changes in addition to
the Ph chromosome are required.
Approved by the FDA in 2001, the tyro-
sine kinase inhibitor imatinib was the
first drug to be designed specifically to
target a molecular defect associated with
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cancer and has revolutionized the man-
agement of CML. Imatinib binds to the
catalytic domain of the ABL1 kinase, pre-
venting ATP binding and trapping it in
an inactive conformation (Druker, 2008).
Newly diagnosed chronic-phase CML pa-
tients treated with imatinib demonstrated
a complete hematologic response of
96% at one year and an overall survival
of 89% at five years (Druker et al., 2006).
However, approximately 6% of chronic-
phase patients relapse and develop resis-
tance to imatinib and many patients who
are first treated during accelerated phase
or blast crisis demonstrate imatinib resis-
tance (Druker, 2008). In the majority of
cases, imatinib resistance is due to point
mutations in BCR-ABL1 that change the
conformation of the ABL1 kinase domain,
preventing imatinib binding. Many of
these mutations can be overcome by
treatment with next-generation tyrosine
kinase inhibitors such as dasatinib or
